Healthcare M&A » By The Online Investor Staff, updated Sat., Aug. 17, 4:32 PM
Recent mergers and acquisitions in the Healthcare M&A category.
| This Slide: #80 of 100 |
Slide #80. Intrexon Corporation — Medistem
Acquirer:
Intrexon Corporation (NASDAQ:XON)
Acquiree:
Medistem (MEDS)
Details:
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has completed the acquisition of San Diego-based Medistem, Inc. (OTCQB: MEDS), a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies. Upon integration of these platforms, ERCs could be manufactured as genetically modified vehicles to secrete powerful therapeutic effectors in the body for clinical benefit to patients suffering from many different diseases.
Intrexon is engaged in the field of synthetic biology, focusing on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. Using its suite of technologies, Co. designs, builds and regulates gene programs, which are DNA sequences that consist of primary genetic components. A single gene program or a complex, multi-genic program is fabricated and stored within a DNA vector. Vectors are segments of DNA used as a vehicle to transmit genetic information. Co.'s primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Hungary.
XON SEC Filing Email Alerts Service
Open the XON Page at The Online Investor »
|
|||||||||||||||||||||
Open the XON Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
 
|
Hold (2.25 out of 4) 7th percentile
(ranked lower than approx. 93% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
